Abbott Laboratories vs. Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc. Common Stock (RNA) comes out ahead, leading on 2 of 3 compared factors.
Size & Scale
| ABT | RNA | |
|---|---|---|
| Market Cap | $182.59 billion | $194.15 million |
| Revenue (TTM) | $46.59 billion | — |
| Net Income (TTM) | $5.42 billion | — |
ABT leads on 1 of 1 size & scale factors.
Valuation
| ABT | RNA | |
|---|---|---|
| P/E Ratio | 34.15 | — |
| Price / Book | 3.53 | 0.90 |
| Price / Sales | 3.92 | — |
RNA leads on 1 of 1 valuation factors.
Profitability
| ABT | RNA | |
|---|---|---|
| Net Margin | 11.65% | — |
| Return on Equity | 10.48% | — |
ABT and RNA split the profitability factors evenly.
Dividend
| ABT | RNA | |
|---|---|---|
| Dividend Yield | 2.39% | — |
| Payout Ratio | 81.55 | — |
ABT and RNA split the dividend factors evenly.
Risk & Sentiment
| ABT | RNA | |
|---|---|---|
| Short Interest | 0.57% | 0.00% |
RNA leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RNA overview, RNA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.